Clinical trial NCT06034145: Methacholine Challenge Testing: Comparison of FEV1 and IOS Parameters in Adult Asthma Patients
Official title: Methacholine Challenge Testing: Comparison of FEV1 and IOS Parameters in Adult Asthma Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Bronchial Hyperreactivity
Keywords: asthma
oscillometry
spirometry
bronchial hyperreactivity
Lead sponsor: Allergi- og Lungeklinikken, Elsinore
Sponsor class: NETWORK
First posted: 2023-09-13
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is a cross-sectional analysis of a single-centered, observational study on adult (≥18 years old) patients referred with known asthma or asthma-like symptoms to a lung specialist clinic

Brief summary: A classic methacholine challenge test is considered positive when forced expiratory volumen after one second (FEV1) decrease 20%. Impulse oscillometry (IOS) measures airway resistance and reactance, and seems more sensitive to changes in small airways. In adult asthma patients, we compare methacholine challenge test using both FEV1 and IOS.

Detailed description: Asthma is a common chronic disease that is characterized by a history of variable respiratory symptoms and variable expiratory airflow limitation, and usually associated with airway hyperresponsiveness (GINA).

In general, FEV1 is used to test for airway hyperresponsiveness (AHR), and a 20% decrease after methacholine challenge is considered a positive test (Coates 2017; ERJ).

There is increasing recognition that the small airways are involved in 40-80% of patients with asthma, and the function of these airways is overlooked (the "silent zone") when measuring FEV1, which mainly reflects the function of the central airways (Cottini M, J Allergy Clin Immunol Pract 2019; Cottini M, 2022; Postma 2019 Lancet Respir Med).

Small airway dysfunction (SAD) can be assessed by IOS where pressure applied to the airways at a range of frequencies, and components of respiratory resistance and reactance are measured. Resistance at 5 Hz (R5) and 20 Hz (R20), respectively, represent total airway resistance and proximal airway resistance. The difference between these two values can be calculated (R5-R20). High R5-R20 and low reactance at 5 Hz (X5) indicate the presence of SAD.

A recent study showed that patients with a negative methacholine test measured by FEV1 may report asthma-like symptoms and may have a positive test when measured by IOS (Urbankowski; 2021). The question is whether these patients are a subgroup of patients with SAD (based on IOS at baseline) or are characterized in another way.

Knowledge on the proportion of patients with AHR only measured by IOS (not by FEV1) and the characteristics of these patients are sparse.

Hypothesis \& Aims The aim of the present study was to determine the proportion of AHR to methacholine measured by FEV1 and IOS, respectively, in patients with diagnosed asthma and to compare patient characteristics and asthma medication in these four groups of patients: 1) negative by FEV1 and IOS; 2) negative by FEV1 but positive by IOS; 3) positive by FEV1 but negative by IOS; 4) positive by both tests.

Eligibility criteria: Inclusion Criteria:

* Doctor diagnosed asthma (based on symptoms and at least one positive asthma test within the last 5 years (AHR; reversibility to beta2-agonist, ICS, prednisolone; peak flow variation).
* Written informed consent.

Exclusion Criteria:

* patients aged less than 18 years old.
* patients with an exacerbation or lower airway infection within 1 months.
* Pulmonary function test: FEV1 (% pred.) \< 60%
* Not able to perform spirometry or body plethysmography.
* Cognitive disorders and not able to answer ACQ.
* Treated with biologics.
* Pregnancy or breastfeeding
* Short-acting beta-agonists 6 h, long-acting beta-agonists 2 days, short-acting anti-muscarinic agent 12 h, Long-acting anti-muscarinic agents 7 days, and Montelukast 3 days before methacholine challenge test (MCT).
* Comorbidity with significant influence on lung function and pulmonary symptoms eg. COPD, bronchiectasis, ischemic heart disease, heart failure, atrial fibrillation, uncontrolled hypertension (\>160/100 mmHg), lung cancer, lung resection, BMI\>40 kg/m2.

Primary outcomes:
measure: ACQ-6
timeFrame: At entry (Cross sectional)
measure: Impulse Oscillometry
timeFrame: At entry
measure: Demographic data
timeFrame: At entry
measure: Biomarker
timeFrame: At entry
measure: FeNO
timeFrame: At entry
measure: Lung function and body box
timeFrame: At entry
measure: Asthma medication
timeFrame: At entry
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Allergy and Lung Clinic Elsinore
name: Thomas Ringbæk, MSci
role: PRINCIPAL_INVESTIGATOR
References: